Therapeutic Advances in Infectious Disease最新文献

筛选
英文 中文
Respiratory pathogen detection and Co-detection in hospitalized children with lower respiratory tract infections using multiplex RT-qPCR: A single-center retrospective Observational Study. 多重RT-qPCR检测住院下呼吸道感染患儿呼吸道病原体及共同检测:一项单中心回顾性观察研究
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261493319
Yunus Nas, Süveyda Gözüküçük, Bekir Sami Uyanık, Basri Çakıroğlu
{"title":"Respiratory pathogen detection and Co-detection in hospitalized children with lower respiratory tract infections using multiplex RT-qPCR: A single-center retrospective Observational Study.","authors":"Yunus Nas, Süveyda Gözüküçük, Bekir Sami Uyanık, Basri Çakıroğlu","doi":"10.1177/20499361261493319","DOIUrl":"https://doi.org/10.1177/20499361261493319","url":null,"abstract":"<p><strong>Background: </strong>Lower respiratory tract infections (LRTIs) are a common cause of pediatric hospitalization, but distinguishing viral from bacterial etiologies based solely on clinical findings remains challenging. Multiplex real-time polymerase chain reaction (RT-qPCR) enables the simultaneous detection of multiple respiratory pathogen targets. However, molecular detection does not necessarily establish microbial causation, particularly for bacteria identified in upper respiratory tract specimens.</p><p><strong>Objectives: </strong>To describe respiratory pathogen detection and co-detection patterns in hospitalized children with LRTIs using multiplex RT-qPCR.</p><p><strong>Design: </strong>A single-center retrospective observational study.</p><p><strong>Methods: </strong>We evaluated 242 hospitalized children with clinically diagnosed LRTIs who underwent multiplex respiratory RT-qPCR testing between October 2021 and April 2026 at a tertiary-care hospital in Istanbul, Türkiye. Nasopharyngeal swab specimens were analyzed for respiratory viral and bacterial targets. All listed targets, including SARS-CoV-2, were assessed in the total study population. Pathogen-specific detection frequencies and single- and multiple-pathogen detection patterns were evaluated. Molecular findings were additionally classified as viral-only, bacterial-only, viral-bacterial co-detection, or no pathogen detected.</p><p><strong>Results: </strong>At least one respiratory pathogen target was detected in 190 of 242 children (78.5%). Among pathogen-positive children, single-pathogen detection occurred in 103 (54.2%) and multiple-pathogen detection in 87 (45.8%). Dual detection was the most frequent multiple-detection pattern (53/87; 60.9%), followed by triple (21/87; 24.1%), quadruple (10/87; 11.5%), quintuple (2/87; 2.3%), and sextuple detection (1/87; 1.1%). The most frequently detected targets were <i>Streptococcus pneumoniae</i> (70/242; 28.9%), <i>Haemophilus influenzae</i> (56/242; 23.1%), and human rhinovirus (37/242; 15.3%). Viral-only detection occurred in 99 children (40.9%), bacterial-only detection in 28 (11.6%), viral-bacterial co-detection in 63 (26.0%), and no pathogen was detected in 52 (21.5%). Detection-pattern distributions differed according to calendar year (p=0.005) and season (p=0.016).</p><p><strong>Conclusion: </strong>Respiratory pathogen detection and co-detection were common among hospitalized children. Viral-only detection was the most frequent pattern. Because nasopharyngeal bacterial detections may reflect upper-airway colonization, these findings should be interpreted as descriptive detection patterns rather than definitive evidence of LRTI causation.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261493319"},"PeriodicalIF":3.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13768632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of perceived stigma and associated factors among patients with tuberculosis in Napak district, Karamoja region, Uganda: A cross-sectional study. 乌干达卡拉莫贾地区Napak区结核病患者中感知到的耻辱感和相关因素的患病率:一项横断面研究。
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-24 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261492617
Victor Lomonyang, Saadick Mugerwa Ssentongo, Ronald Khamasi, Richard JJuuko Kyakuwa, Andrew Katawera, Patricia Nahirya Ntege, William Kasozi, Tadeo Nsubuga, Brenda Picho, Frehd Nghania, Daniel Esogu, Ssekiswa Lwanga Zimwaguyiza, Alexander Mugume, Denise Birungi, Dithan Kiragga
{"title":"Prevalence of perceived stigma and associated factors among patients with tuberculosis in Napak district, Karamoja region, Uganda: A cross-sectional study.","authors":"Victor Lomonyang, Saadick Mugerwa Ssentongo, Ronald Khamasi, Richard JJuuko Kyakuwa, Andrew Katawera, Patricia Nahirya Ntege, William Kasozi, Tadeo Nsubuga, Brenda Picho, Frehd Nghania, Daniel Esogu, Ssekiswa Lwanga Zimwaguyiza, Alexander Mugume, Denise Birungi, Dithan Kiragga","doi":"10.1177/20499361261492617","DOIUrl":"https://doi.org/10.1177/20499361261492617","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) remains a leading cause of infectious disease mortality globally. Stigma is a critical social determinant that undermines health-seeking behavior and treatment adherence, threatening TB control. The Karamoja region in Uganda has the highest TB burden and continues to face unique challenges that affect treatment success.</p><p><strong>Objectives: </strong>This study aimed to determine the prevalence of perceived TB stigma and the factors associated with it among patients with tuberculosis in Napak district, Karamoja.</p><p><strong>Design: </strong>A cross-sectional study was conducted among 385 TB patients aged ≥18 years from three public health facilities in Napak district.</p><p><strong>Methods: </strong>Data were collected via structured interviews using simple random sampling. Perceived stigma was measured using the Van Rie TB Stigma Scale (VTSS), which ranges from 0 to 36 points using a four-point Likert scale. The primary outcome was perceived TB stigma. Individuals with a stigma score greater than the median were categorised as having high stigma, and those at or below the median had low TB stigma. A modified Poisson regression model with robust standard errors was used to identify the factors associated with perceived stigma. A p-value < 0.05 was considered significant.</p><p><strong>Results: </strong>We enrolled 385 participants. Overall, 59.5% (n=229) were male, and 43.4% (n=167) were aged ≥43 years. The prevalence of high TB stigma was 43.1% (n=166) (95% CI: 38.2-48.1%). In adjusted analysis, high TB stigma was significantly more likely among participants with secondary education (aRR: 1.53; 95% CI: 1.14-2.06, p=0.005) as compared to those with no education, those who did not have adequate social support (aRR: 1.36; 95% CI: 1.07-1.72, p=0.01) as compared to those who had. In addition, participants with overall poor knowledge and perception of TB (aRR: 1.72; 95% CI: 1.28-2.30, p < 0.001) had high TB stigma as compared to those with good knowledge of TB.</p><p><strong>Conclusions: </strong>Perceived stigma is prevalent among TB patients in the Napak district and is strongly associated with having secondary-level education, lack of social support, and having poor knowledge and perception of TB. Interventions must integrate community education to demystify transmission and reduce fear, while strengthening psychosocial support systems to reduce stigma among TB patients.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261492617"},"PeriodicalIF":3.8,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13768660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of active pulmonary tuberculosis and implications of a novel mining risk factor for TB control: An unmatched case-control study in Guji Zone, Oromia Region, Ethiopia. 活动性肺结核的决定因素和一种新的采矿危险因素对结核病控制的影响:埃塞俄比亚奥罗米亚地区古集地区的一项无与伦比的病例对照研究。
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-23 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261492594
Abera Siyum, Anteneh Fikrie Tekola, Gemechis Tuke, Kidist Bobosha, Berhanu Seyoum
{"title":"Determinants of active pulmonary tuberculosis and implications of a novel mining risk factor for TB control: An unmatched case-control study in Guji Zone, Oromia Region, Ethiopia.","authors":"Abera Siyum, Anteneh Fikrie Tekola, Gemechis Tuke, Kidist Bobosha, Berhanu Seyoum","doi":"10.1177/20499361261492594","DOIUrl":"https://doi.org/10.1177/20499361261492594","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) remains a major global health challenge, especially in low-income countries like Ethiopia. Despite ongoing control efforts, TB remains prevalent, highlighting the need for more in-depth research. Guji Zone of Oromia Region is among high TB burden zones in Ethiopia with a new case detection rate of 279/100,000 population in 2016 Ethiopian Fiscal Year (EFY).</p><p><strong>Objectives: </strong>This study was aimed to identify the determinants of active PTB, with particular emphasis on the impact of mining, as well as other occupational and structural factors.</p><p><strong>Design: </strong>A facility-based unmatched case-control study was conducted from August 1 to December 30, 2024<b>.</b></p><p><strong>Methods: </strong>The study was conducted among randomly selected 735 (cases 245 and controls 490) patients in Guji zone from August 2024 to December 2024. A pretested and structured face-to-face interviewer administered questionnaire and chart review were used to collect the data. Data was entered into Epi Data version 4.6.0 and exported to SPSS version 25.0 for analysis. Bi-variable and multi variable binary logistic regression model were used to identify the determinants of active PTB. Adjusted odds ratio with 95% Confidence level and p-value of <0.05 were used to declare statistically significant associations.</p><p><strong>Results: </strong>A total of 735 study participants comprising 245 cases and 490 controls aged 15 years and above were included, with an overall response rate of 99.6%. Being HIV-positive (AOR = 3.47, 95% CI: 1.95-6.11), cigarette smoking (AOR = 2.84, 95% CI: 1.78-4.51), having a body mass index (BMI) of below 18.5 (AOR = 2.55, 95% CI: 1.24-5.24), daily laborer (AOR = 2.31, 95% CI: 1.30-4.09), having a history of contact with a known TB patient (AOR = 2.92, 95% CI: 1.95-4.36), limited access to health facilities (AOR = 1.76, 95% CI: 1.15-2.71), and poor knowledge of TB (AOR = 2.27, 95% CI: 1.47-3.51) were significantly associated with active PTB. A key novel finding of this analysis is the prominent association between mining occupations and active PTB, with miners exhibiting over three times the odds of developing the disease compared to non-miners (AOR = 3.51, 95% CI: 1.89-6.50).</p><p><strong>Conclusion: </strong>Our study identified a set of determinants for active PTB, including HIV infection, low BMI, cigarette smoking, mining and daily laborer occupations, poor TB knowledge, history of contact with known TB patient, and limited access to healthcare. Crucially, this study uncovers a novel occupational hazard: mining occupation was independently associated with active PTB. Mitigating this burden requires integrating occupational health interventions, specifically targeted screening and safety protocols within mining communities, into broader TB control strategies.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261492594"},"PeriodicalIF":3.8,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13760112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales. 模拟在英格兰和威尔士预防婴幼儿呼吸道合胞病毒的clesrovimab的潜在临床和经济影响。
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-17 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261483967
Klodeta Kura, Colleen Burgess, Ian R Matthews, Salisu M Garba, Dawei Wang, John C Lang, Dionysios Ntais, Yao-Hsuan Chen
{"title":"Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales.","authors":"Klodeta Kura, Colleen Burgess, Ian R Matthews, Salisu M Garba, Dawei Wang, John C Lang, Dionysios Ntais, Yao-Hsuan Chen","doi":"10.1177/20499361261483967","DOIUrl":"10.1177/20499361261483967","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) infects nearly all children under two years, causing mild lower respiratory tract infections (LRTIs) although serious disease, mortality and long-term recurrent wheezing can also occur.</p><p><strong>Objectives: </strong>This study evaluates the health and economic impact of various RSV prevention strategies (monoclonal antibodies [mAb] such as clesrovimab, nirsevimab, palivizumab [high risk infants only] or maternal vaccination) in infants in England and Wales.</p><p><strong>Design: </strong>A previously published decision tree model was adapted to estimate RSV LRTIs and associated costs over one year among a cohort of infants entering their first RSV season in England and Wales.</p><p><strong>Methods: </strong>Clinical trial data were used for efficacy inputs alongside country-specific epidemiology and costs to assess the impact of year-round and seasonal mAb programs (without and with catch-up [for infants born out of season]) alongside maternal vaccination. Deterministic sensitivity analyses of incremental treatment costs and QALYs were performed.</p><p><strong>Results: </strong>Seasonal administration of clesrovimab with and without catch-up led to fewer RSV-associated LRTI cases and lower treatment costs compared to other RSV intervention strategies. Without catch-up, clesrovimab reduced RSV-LRTI cases by 18%-27% versus palivizumab, 3%-4% versus nirsevimab and 2%-13% versus maternal vaccine. With catch-up, RSV-LRTI outcomes reductions by clesrovimab were greater: 60%-70% versus palivizumab, 14%-20% versus nirsevimab, and 43%-54% versus maternal vaccination. It also reduced treatment costs by £37.0 million compared to palivizumab, £4.0 million compared to nirsevimab, and £26.0 million compared to maternal vaccination. Coverage and efficacies were the most influential parameters.</p><p><strong>Conclusions: </strong>Clesrovimab is projected to substantially reduce RSV-associated clinical outcomes and costs compared to both standard of care and potential new RSV prevention measures in England and Wales.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261483967"},"PeriodicalIF":3.8,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149325836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Closing the therapeutic drug monitoring gap: A pragmatic, complementary lever against antimicrobial resistance in low- and middle-income countries. 缩小治疗药物监测差距:低收入和中等收入国家抗微生物药物耐药性的一个务实的补充杠杆。
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-16 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261481600
Mamunur Rahman
{"title":"Closing the therapeutic drug monitoring gap: A pragmatic, complementary lever against antimicrobial resistance in low- and middle-income countries.","authors":"Mamunur Rahman","doi":"10.1177/20499361261481600","DOIUrl":"10.1177/20499361261481600","url":null,"abstract":"","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261481600"},"PeriodicalIF":3.8,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149325835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacterial profile and antimicrobial resistance patterns of infected diabetic foot ulcers in low- and middle-income countries: a systematic review and meta‑analysis. 低收入和中等收入国家感染糖尿病足溃疡的细菌概况和抗微生物药物耐药性模式:系统回顾和荟萃分析
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-15 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261452940
Aaron Awere-Duodu, Frederick Kungu, Yacoba Atiase, Eric S Donkor
{"title":"Bacterial profile and antimicrobial resistance patterns of infected diabetic foot ulcers in low- and middle-income countries: a systematic review and meta‑analysis.","authors":"Aaron Awere-Duodu, Frederick Kungu, Yacoba Atiase, Eric S Donkor","doi":"10.1177/20499361261452940","DOIUrl":"10.1177/20499361261452940","url":null,"abstract":"<p><strong>Background: </strong>Diabetic foot ulcers (DFUs) are often polymicrobial infections, necessitating antibiotic therapy. However, the high prevalence of antibiotic misuse and the growing issue of antibiotic resistance in low- and middle-income countries (LMICs) exacerbate the challenges in managing these ulcers, contributing to the risk of lower-limb amputations.</p><p><strong>Objectives: </strong>This systematic review reported the bacterial profile and antibiotic resistance patterns associated with DFUs in LMICs.</p><p><strong>Design: </strong>A systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>A comprehensive search was conducted in PubMed, SCOPUS, and Web of Science to retrieve relevant articles, which were screened according to predefined selection criteria. Publication bias was assessed with a funnel plot and Egger's regression test. A meta-analysis was conducted in RStudio version 4.5.2, using the random-effects model. Meta-regression and sensitivity analysis were conducted to assess the sources of heterogeneity and robustness of the included studies, respectively.</p><p><strong>Results: </strong>The most frequently isolated bacteria were <i>Staphylococcus aureus</i> (22.64%), <i>Escherichia coli</i> (12.37%), <i>Pseudomonas aeruginosa</i> (8.49%), <i>Klebsiella pneumoniae</i> (5.19%), <i>P. mirabilis</i> (4.61%), and Coagulase-negative <i>Staphylococci</i> (4.86%). The prevalence of key antibiotic-resistant bacteria was as follows: Methicillin-resistant <i>S. aureus</i> (38.65%), Extended-spectrum beta-lactamase (ESBL)-producing <i>E. coli</i> (50.74%), and ESBL-producing <i>K. pneumoniae</i> (41.54%). <i>S. aureus</i> demonstrated the highest resistance to penicillin (96.87% (93.30; 99.32)), azithromycin (76.42% (64.54; 86.65)), and cefoxitin (68.19% (46.83; 86.67)). <i>E. coli</i> showed the highest resistance to ampicillin (86.60% (77.14; 94.18)) and cotrimoxazole (69.27% (57.35; 80.18)).</p><p><strong>Conclusion: </strong>Pathogenic bacteria isolated from DFUs in LMICs exhibit high rates of antibiotic and multidrug resistance. Alternative therapies, such as phage therapy, should be explored as potential treatments for DFUs to mitigate the impact of antibiotic resistance and decrease the rate of diabetes-related amputations.</p><p><strong>Trial registration: </strong>Open Science Framework (OSF) registry, available at https://doi.org/10.17605/OSF.IO/DPX9F.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261452940"},"PeriodicalIF":3.8,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13583299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic factors in the selection of antivirals for COVID-19 in high-risk outpatients: A retrospective cohort study. 高危门诊患者COVID-19抗病毒药物选择的预后因素:一项回顾性队列研究
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-14 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261473780
Puttirat Bunditwongpaisan, Natthakit Chavapradit
{"title":"Prognostic factors in the selection of antivirals for COVID-19 in high-risk outpatients: A retrospective cohort study.","authors":"Puttirat Bunditwongpaisan, Natthakit Chavapradit","doi":"10.1177/20499361261473780","DOIUrl":"10.1177/20499361261473780","url":null,"abstract":"<p><strong>Background: </strong>Early oral antiviral treatment reduced disease progression and hospitalisation in high-risk COVID-19 outpatients. In practice, prescribing decisions were influenced by clinical risk, drug interaction concerns, and physician judgment, even in settings where guidelines prioritised nirmatrelvir/ritonavir. This study aimed to identify the patient characteristics that independently predicted oral antiviral selection.</p><p><strong>Objectives: </strong>To identify (1) independent predictors of nirmatrelvir/ritonavir versus molnupiravir prescribing, and (2) predictors of receiving any potent antiviral versus no potent antiviral, among high-risk COVID-19 outpatients.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>Using data from Bhumibol Adulyadej Hospital in Bangkok, Thailand, this retrospective cohort study enrolled 450 COVID-19 outpatients between April 2022 and June 2023. Participants were randomly selected into three treatment groups of 150 each: nirmatrelvir/ritonavir, molnupiravir, and no antiviral. Multivariate logistic regression was applied to identify independent predictors of drug selection across demographics, comorbidities, and concomitant medications.</p><p><strong>Results: </strong>Treated patients were older than those who received no antiviral, with mean ages of 61.68 and 62.91 years in the nirmatrelvir/ritonavir and molnupiravir groups versus 43.89 years in the no-treatment cohort (p < 0.001). Comorbid disease was more prevalent in both antiviral groups. When nirmatrelvir/ritonavir and molnupiravir recipients were compared directly, concurrent statin use was the only variable that independently predicted a lower probability of nirmatrelvir/ritonavir being chosen (adjusted OR 0.46; 95% CI 0.27 to 0.79; p = 0.005).</p><p><strong>Conclusion: </strong>Older patients and those carrying a greater comorbidity burden were prioritised for antiviral treatment in this Thai outpatient cohort. Drug-drug interaction concerns, particularly between ritonavir and statins, drove physicians toward molnupiravir even when nirmatrelvir/ritonavir would otherwise have been the preferred agent. Systematic incorporation of pharmacist-conducted medication assessment before antiviral prescribing represents a practicable strategy for reducing avoidable drug substitution in high-risk patients.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261473780"},"PeriodicalIF":3.8,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13583282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: Treatment gaps and risk factors for multidrug-resistant Enterobacterales in Belize: A 6-year (2018-2023) nationwide retrospective analysis. 评论:伯利兹耐多药肠杆菌的治疗差距和风险因素:一项为期6年(2018-2023)的全国回顾性分析。
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-10 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261487109
Ana Moragas, Carl Llor
{"title":"Comment on: Treatment gaps and risk factors for multidrug-resistant Enterobacterales in Belize: A 6-year (2018-2023) nationwide retrospective analysis.","authors":"Ana Moragas, Carl Llor","doi":"10.1177/20499361261487109","DOIUrl":"10.1177/20499361261487109","url":null,"abstract":"","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261487109"},"PeriodicalIF":3.8,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing HIV care in daily life: A qualitative study of ART adherence and retention barriers and facilitators among people attending two urban ART clinics in Panama. 管理日常生活中的艾滋病毒护理:巴拿马两家城市抗逆转录病毒治疗诊所的患者坚持和保留抗逆转录病毒治疗的障碍和促进因素的定性研究。
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-09 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261488579
Amanda Gabster, Dixennia Bejarano, Lisa Hightow-Weidman, Jennifer Toller Erausquin, Artur Luz Nunes Queiroz, Casey D Xavier Hall, Frank Frankie Wong, Carlos Chávez Sáenz, Gonzalo Cabezas Talavero, Ana Belén Araúz, Cristel Rodríguez-Vargas, Felix Díaz Fernández, Eugenia Flores Millender
{"title":"Managing HIV care in daily life: A qualitative study of ART adherence and retention barriers and facilitators among people attending two urban ART clinics in Panama.","authors":"Amanda Gabster, Dixennia Bejarano, Lisa Hightow-Weidman, Jennifer Toller Erausquin, Artur Luz Nunes Queiroz, Casey D Xavier Hall, Frank Frankie Wong, Carlos Chávez Sáenz, Gonzalo Cabezas Talavero, Ana Belén Araúz, Cristel Rodríguez-Vargas, Felix Díaz Fernández, Eugenia Flores Millender","doi":"10.1177/20499361261488579","DOIUrl":"10.1177/20499361261488579","url":null,"abstract":"<p><strong>Background: </strong>Optimal antiretroviral therapy (ART) adherence and retention in HIV care are important for viral suppression among people living with HIV (PLHIV). Although ART is free in Panamanian public clinics, ART adherence and care continuity remain challenges. Prior studies in Panama have described quantitative correlates of adherence in urban clinics and barriers in a rural Indigenous region but less is known about how urban clinic attendees in Panama City and Colón experience adherence and retention in everyday contexts.</p><p><strong>Objectives: </strong>To describe the barriers and facilitators to ART adherence and retention, and how PLHIV manage HIV care in everyday life among PLHIV attending two urban clinics using the socioecological framework.</p><p><strong>Design: </strong>Qualitative study using semi-structured interviews organized and interpreted using the socioecological framework.</p><p><strong>Methods: </strong>Between August-November 2024, 20 semi-structured interviews were conducted among PLHIV attending two urban ART clinics (Hospital Santo Tomás and Colón Regional Clinic) in Panama. Participants were purposively selected. Interviews were 30-60 minutes long, audio-recorded, transcribed, inductively coded and then organized thematically across socioecological levels.</p><p><strong>Results: </strong>Twenty participants were included (11 identified as men, 8 cisgender women and one transgender woman); median age was 38.5 years. ART Adherence was supported by medication routines, phone alarms, alternative pill containers, family and partner reminders, supportive health personnel and clinic-delivered education. Retention in care was supported by prioritizing appointments, planning around work and transportation, supportive health personnel, clinic education, transportation availability and advance scheduling. ART adherence and retention were disrupted by emotional distress, demotivation, side effects, forgetfulness, limited family support, stigma and disclosure concerns, rumors and harassment, poor communication with health personnel, pharmacy stockouts, food insecurity, transport costs and time or financial barriers.</p><p><strong>Conclusion: </strong>ART adherence and retention are interconnected parts of daily HIV disease management and are influenced by individual, interpersonal, organizational and structural factors. Urban HIV services could benefit from patient-centered adherence support, confidentiality protections, responsive side-effect management, treatment literacy and support for transport, food insecurity and ART access.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261488579"},"PeriodicalIF":3.8,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of alanine aminotransferase flares with hepatitis B surface antigen loss and clinical outcomes in treated and untreated patients with chronic hepatitis B virus infection: A US retrospective cohort study. 慢性乙型肝炎病毒感染治疗和未治疗患者的丙氨酸转氨酶与乙型肝炎表面抗原丢失和临床结局的关联:一项美国回顾性队列研究
IF 3.8
Therapeutic Advances in Infectious Disease Pub Date : 2026-09-08 eCollection Date: 2026-01-01 DOI: 10.1177/20499361261473788
Myriam Drysdale, Eleonora Morais, Rose Chang, Shuang Wang, Megan Pinaire, Manasi Mohan, Rui Song, Mei Shung Duh, Grace Dolman, Dickens Theodore, Iain A Gillespie
{"title":"Association of alanine aminotransferase flares with hepatitis B surface antigen loss and clinical outcomes in treated and untreated patients with chronic hepatitis B virus infection: A US retrospective cohort study.","authors":"Myriam Drysdale, Eleonora Morais, Rose Chang, Shuang Wang, Megan Pinaire, Manasi Mohan, Rui Song, Mei Shung Duh, Grace Dolman, Dickens Theodore, Iain A Gillespie","doi":"10.1177/20499361261473788","DOIUrl":"10.1177/20499361261473788","url":null,"abstract":"<p><strong>Background: </strong>Previous research has demonstrated the clinical significance of alanine aminotransferase (ALT) flares; however, studies have mostly been in Asian countries or populations, and it remains unclear whether ALT flares during treatment are associated with hepatitis B surface antigen (HBsAg) loss and long-term adverse clinical outcomes.</p><p><strong>Objectives: </strong>To evaluate the association between ALT flares and virologic outcomes (HBsAg and hepatitis B e antigen [HBeAg] loss) as well as adverse clinical outcomes among patients with chronic hepatitis B in the United States, according to treatment status.</p><p><strong>Design: </strong>Retrospective study using the Optum de-identified electronic health record dataset (2012-2019).</p><p><strong>Methods: </strong>Marginal structural models estimated the associations between ALT flares and outcomes, accounting for time-varying confounding; adjusted odds ratios and 95% confidence intervals were reported. A Cox proportional hazards regression model was used to assess risk factors for flares.</p><p><strong>Results: </strong>14,328 patients were included in the untreated cohort; of these, 2298 (16.0%) initiated and 1541 (10.7%) subsequently discontinued treatment. At least one ALT flare was experienced by 364 patients (2.5%) in the untreated cohort, 84 (3.7%) in the treatment initiation cohort, and 22 (1.4%) in the discontinuation cohort. Risk factors for ALT flares in the untreated group included male sex, history of flares, metabolic syndrome, liver fibrosis, compensated cirrhosis (CC), and hepatic decompensation. Risk factors after treatment initiation included younger age, White race, history of flares, and evidence of liver damage (liver fibrosis, CC, or hepatic decompensation). Flares in the untreated group were associated with spontaneous HBsAg loss and with an increased risk of hepatic decompensation, hospitalization, and death. Flares after treatment initiation were associated with HBsAg and HBeAg loss but not with adverse clinical outcomes investigated.</p><p><strong>Conclusion: </strong>ALT flares in untreated patients were associated with virologic and adverse clinical outcomes; no association with adverse clinical outcomes was observed in patients who initiated treatment.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"13 ","pages":"20499361261473788"},"PeriodicalIF":3.8,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13554665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书